Get the Stockscreener App
3.815
6.47%
0.1521
Xenetic Biosciences Inc stock is traded at $3.815, with a volume of 14,775.
It is up +6.47% in the last 24 hours and down -13.71% over the past month.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.
See More
Previous Close:
$3.6629
Open:
$3.74
24h Volume:
14,775
Relative Volume:
0.83
Market Cap:
$5.65M
Revenue:
$2.54M
Net Income/Loss:
$-4.13M
P/E Ratio:
-1.3201
EPS:
-2.89
Net Cash Flow:
$-4.11M
1W Performance:
+5.12%
1M Performance:
-13.71%
6M Performance:
-8.67%
1Y Performance:
+20.00%
1-Day Range:
$3.60
$3.98
1-Week Range:
$3.60
$4.65
52-Week Range:
$2.78
$5.20
Xenetic Biosciences Inc Stock (XBIO) Company Profile
Name
Xenetic Biosciences Inc
Sector
Industry
Phone
781-778-7720
Address
945 CONCORD ST., FRAMINGHAM, MA
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-20 | Initiated | Maxim Group | Buy |
Xenetic Biosciences Inc Stock (XBIO) Latest News
Xenetic Biosciences announces board member changes - Investing.com India
Xenetic Biosciences announces board member changes By Investing.com - Investing.com UK
Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Grows By 460.0% - Defense World
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 - AccessWire
SEC Form S-3 filed by Xenetic Biosciences Inc. - Quantisnow
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform - AccessWire
Xenetic partners with Tokyo Medical for cancer treatment study - Investing.com
Secondary Progressive Multiple Sclerosis Drug Market to Expand with Significant CAGR by 2034 |AB Science SA, Actelion Lt – IndiaPolitics.com - IndiaPolitics.com
Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Drops By 50.0% - Defense World
Xenetic Biosciences Inc (NASDAQ:XBIO) Sees Significant Decline in Short Interest - Defense World
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference - Kansas City Star
Q3 2024 Earnings Estimate for Xenetic Biosciences Inc (NASDAQ:XBIO) Issued By HC Wainwright - Defense World
XBIO Stock Earnings: Xenetic Biosciences Meets EPS, Beats Revenue for Q2 2024 - MSN
Xenetic Biosciences (NASDAQ:XBIOW) Stock Price Up 33.9% - Defense World
Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates - MSN
Xenetic Biosciences (NASDAQ:XBIO) Earns “Neutral” Rating from HC Wainwright - Defense World
Xenetic Biosciences Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line - Simply Wall St
Xenetic Biosciences (NASDAQ:XBIO) Releases Earnings Results, Hits Estimates - Defense World
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update - Markets Insider
Xenetic Biosciences: Q2 Earnings Snapshot - CTPost
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Up 3,550.0% in July - Defense World
ElectroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Canada Finance
Xenetic Biosciences stock hits 52-week low at $2.78 By Investing.com - Investing.com Canada
Xenetic Biosciences stock hits 52-week low at $2.78 - Investing.com India
Takeda Pharmaceutical (TAK) Stock Price, News & Analysis - MarketBeat
Global Chronic Kidney Disease (CKD) Drug Market 2024 Analysis by Top Key Players |Abbott Laboratories - The NRI News
CANADA LIFE ASSURANCE Co Grows Stock Position in Tapestry, Inc. (NYSE:TPR) - American Banking and Market News
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Down 93.0% in July - Defense World
Xenetic Biosciences, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results - Quantisnow
WiMi Hologram Cloud Inc. (NASDAQ:WIMI) Sees Large Growth in Short Interest - Defense World
Short Interest in Wearable Devices Ltd. (NASDAQ:WLDS) Declines By 51.0% - American Banking and Market News
Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Decreases By 18.1% - American Banking and Market News
Welsbach Technology Metals Acquisition Corp. (NASDAQ:WTMA) Short Interest Update - American Banking and Market News
Bird Construction Inc. (OTCMKTS:BIRDF) Short Interest Update - American Banking and Market News
(XBIOW) Trading Advice - Stock Traders Daily
Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference - Quantisnow
Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update - Quantisnow
Xenetic Biosciences (NASDAQ:XBIOW) Trading Up 17.5% - Defense World
Xenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Sport Australia
Long Term Trading Analysis for (XBIOW) - Stock Traders Daily
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference - Quantisnow
VAXART, INC. (VXRT) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Lifestyle Australia
Xenetic Biosciences reports management changes and compensatory arrangements By Investing.com - Investing.com
Xenetic Biosciences Announces Executive Leadership RestructuringTipRanks.com - TipRanks
Xenetic Biosciences Inc Stock (XBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):